24
Views
2
CrossRef citations to date
0
Altmetric
Miscellaneous

Indole-based CXC chemokine receptor-2 antagonists

Pages 721-723 | Published online: 02 Mar 2005

Bibliography

  • EHLERT JE: Chemokines and chemokine : disease targets for therapeutic development. Expert Opin. Invest. Drugs (2000) 9:627–629.
  • •Good review of the therapeutic potential of chemokine antagonism.
  • ONUFFER JJ, HORUK R: Chemokines, chemokine receptors and small-molecule antagonists: recent developments. Phannacol. Sri. (2002) 23:459–467.
  • ••Very useful recent review of the literature.
  • BARNES PJ: Potential novel therapies forchronic obstructive pulmonary disease. Novartis Found. Symp (2001) 234:255-267; discussion 267–272.
  • WILLIAMS TJ, JOSE PJ: Neutrophils inchronic obstructive pulmonary disease. Novartis Found. Symp (2001) 234:136-141; discussion 141–148.
  • BOISVERT WA, CURTISS LK, TERKELTAUB RA: Interleuldn-8 and its receptor CXCR2 in atherosclerosis. Inonunol. Res (2000) 21(2-3):129–137.
  • PODOLIN PL, BOLOGNESE BJ, FOLEY JJ et al: A potent and selective non-peptide antagonist of CXCR2 inhibits acute and chronic models of arthritis in the rabbit. J. Inununol. (2002) 169:6435–6454.
  • •Highlighting the potential of CXCR2 antagonists in arthritis.
  • JIE JACK LI: Small molecule interleukin-8. Expert Opin. Ther. Patents(2001) 11:1905–1910.
  • ••Recent review of CXCR2 and CXCR1 and the patent literature.

Websites

  • www.astrazenecaa.com/downloads/ HY- 192002-pipeline.pdf

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.